Table. 1.
Comparison of the two groups in demographic and in disease-related factors.
| Control Group CTX 4 g/m2 + G-CSF |
PLX on-demand Study Group | P | |
|---|---|---|---|
| N | 138 | 138 | |
| Gender: male, n (%) | 91 (66%) | 87 (63%) | 0.53 |
| Median Age, years | 55.5 | 59.4 | 0.0001 |
| (IQR) | (10) | (11) | |
| IgG Type, n (%) | NA | 102/138 (73.9%) | – |
| IgA Type, n (%) | 22/138 (15.9%) | ||
| light chain, n (%) | 14/138 (10.1%) | ||
| Stage | NA | I°: 12/138 (8.6%) | – |
| (Durie and Salmon), n (%) | II°: 32/138 (23.1%) | ||
| III°:94/138 (68.2%) | |||
| First-line treatment containing bortezomib: | |||
| VTD or VD, n (%) | NA | 132 (96%) | – |
| other schemes, n (%) | 6 (4%) | ||
| Response to induction | |||
| CR/VGPR, n (%) | 32 (23.1%) | 59 (42.5%) | 0.0001 |
| PR/SD, n (%) | 106 (76.9%) | 79 (57.5%) | |
| WBC in PB at the start of mobilization | |||
| Median, cells × 106/mL | 5,380 | 5,960 | 0.003 |
| (IQR) | (2,290) | (2,375) | |
| Platelets in PB at the start of mobilization | |||
| Median, cells × 106/mL | 214,000 | 220,000 | 0.25 |
| (IQR) | (69,000) | (79,000) | |
| Dose of G-CSF | |||
| 10 μg/kg, n (%) | 55/138 (39.8%) | 138/138 (100%) | 0.0001 |
| Previous | |||
| Radiotherapy, n (%) | 125/138 (8%) | 29/138 (21%) | 0,64 |